Literature DB >> 25882738

Macrophage migration inhibitory factor: a key cytokine and therapeutic target in colon cancer.

A N Gordon-Weeks1, S Y Lim2, A E Yuzhalin2, K Jones2, R Muschel2.   

Abstract

Macrophage migration inhibitory factor (MIF) was one of the first cytokines to be discovered, over 40 years ago. Since that time a burgeoning interest has developed in the role that MIF plays in both the regulation of normal physiology and the response to pathology. MIF is a pleotropic cytokine that functions to promote inflammation, drive cellular proliferation, inhibit apoptosis and regulate the migration and activation state of immune cells. These functions are particularly relevant for the development of cancer and it is notable that various solid tumours over express MIF. This includes tumours of the gastrointestinal tract and MIF appears to play a particularly prominent role in the development and progression of colonic adenocarcinoma. Here we review the role that MIF plays in colonic carcinogenesis through the promotion of colonic inflammation, as well as the progression of primary and metastatic colon cancer. The recent development of various antagonists and antibodies that inhibit MIF activity indicates that we may soon be able to classify MIF as a therapeutic target in colon cancer patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colon cancer; Inflammation; MIF; Macrophage migration inhibitory factor

Mesh:

Substances:

Year:  2015        PMID: 25882738     DOI: 10.1016/j.cytogfr.2015.03.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  17 in total

1.  Deletion of macrophage migration inhibitory factor inhibits murine oral carcinogenesis: Potential role for chronic pro-inflammatory immune mediators.

Authors:  Steve Oghumu; Thomas J Knobloch; Cesar Terrazas; Sanjay Varikuti; Jennifer Ahn-Jarvis; Claire E Bollinger; Hans Iwenofu; Christopher M Weghorst; Abhay R Satoskar
Journal:  Int J Cancer       Date:  2016-06-16       Impact factor: 7.396

2.  The Long-term Impact of Roux-en-Y Gastric Bypass on Colorectal Polyp Formation and Relation to Weight Loss Outcomes.

Authors:  Hisham Hussan; Alyssa Drosdak; Melissa Le Roux; Kishan Patel; Kyle Porter; Steven K Clinton; Brian Focht; Sabrena Noria
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

Review 3.  Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer.

Authors:  Camila Cristina Guimarães Nobre; Josélio Maria Galvão de Araújo; Thales Allyrio Araújo de Medeiros Fernandes; Ricardo Ney Oliveira Cobucci; Daniel Carlos Ferreira Lanza; Vânia Sousa Andrade; José Veríssimo Fernandes
Journal:  Pathol Oncol Res       Date:  2016-10-23       Impact factor: 3.201

4.  Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis.

Authors:  Ming-Sheng Fu; Shu-Xian Pan; Xun-Quan Cai; Yuan-Xin Hu; Wei-Jie Zhang; Qin-Cong Pan
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

5.  Discovery of chromenes as inhibitors of macrophage migration inhibitory factor.

Authors:  Tjie Kok; Hannah Wapenaar; Kan Wang; Constantinos G Neochoritis; Tryfon Zarganes-Tzitzikas; Giordano Proietti; Nikolaos Eleftheriadis; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Robbert H Cool; Gerrit J Poelarends; Alexander Dömling; Frank J Dekker
Journal:  Bioorg Med Chem       Date:  2017-12-24       Impact factor: 3.641

Review 6.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

7.  MiR-451 as a new tumor marker for gastric cancer.

Authors:  Yong Shen; Jiao-Mei Gong; Li-Li Zhou; Jia-He Sheng
Journal:  Oncotarget       Date:  2017-04-19

8.  Identification of differentially expressed inflammatory factors in Wilms tumors and their association with patient outcomes.

Authors:  Fei Guo; Junjie Zhang; Lei Wang; Wei Zhao; Jiekai Yu; Shu Zheng; Jiaxiang Wang
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

9.  Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.

Authors:  Martyna Parol-Kulczyk; Arkadiusz Gzil; Joanna Maciejewska; Magdalena Bodnar; Dariusz Grzanka
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

10.  Human mast cells promote colon cancer growth via bidirectional crosstalk: studies in 2D and 3D coculture models.

Authors:  Yingxin Yu; Bart Blokhuis; Yvonne Derks; Sangeeta Kumari; Johan Garssen; Frank Redegeld
Journal:  Oncoimmunology       Date:  2018-08-24       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.